Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis

Journal of Cellular Physiology

Volumn 228, Issue 11, 2013, Pages 2139-2148

  Al Husein, Belal ^a,b   Goc, Anna ^a,b   Somanath, Payaningal R ^a,b,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; BETA CATENIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; SIMVASTATIN; VASCULOTROPIN A; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROMETASTASIS; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; WESTERN BLOTTING;

BETA CATENIN; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MEMBRANE; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; INTERCELLULAR ADHESION MOLECULE-1; MALE; MODELS, BIOLOGICAL; NEOPLASM MICROMETASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN STABILITY; SIMVASTATIN;

EID: 84881230082     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24381     Document Type: Article

References (37)

1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J. 1980. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77:3957-3961.
2. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. 2012. Antiangiogenic therapy for cancer: An update. Pharmacotherapy 32:1095-1111.
3. Brown M, Hart C, Tawadros T, Ramani V, Sangar V, Lau M, Clarke N. 2012. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 106:1689-1696.
4. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, Byzova TV. 2005. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 11:1188-1196.
5. Chen J, Liu B, Yuan J, Yang J, Zhang J, An Y, Tie L, Pan Y, Li X. 2012. Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production. Mol Oncol 6:62-72.
6. Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B. 2009. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl) 87:507-514.
7. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. 1986. Induction by IL 1 and interferon-gamma: Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137:245-254.
8. Gale NW, Thurston G, Davis S, Wiegand SJ, Holash J, Rudge JS, Yancopoulos GD. 2002. Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harb Symp Quant Biol 67:267-273.
9. Gauthaman K, Manasi N, Bongso A. 2009. Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 157:962-973.
10. Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, Greenberg NM, Kreisberg JI. 1999. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18:4120-4130.
11. Goc A, Al-Husein B, Kochuparambil ST, Liu J, Heston WW, Somanath PR. 2011. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Int J Oncol 38:267-277.
12. Goc A, Abdalla M, AL-Azayzih A, Somanath PR. 2012a. Rac1 activation driven by 14-3-3zeta dimerization promotes prostate cancer cell-matrix interactions, motility and transendothelial migration. PLoS ONE 7:e40594.
13. Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S, Somanath PR. 2012b. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 12:409.
14. Goc A, Kochuparambil ST, AL-Husein B, Al-Azayzih A, Mohammad S, Somanath PR. 2012c. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 12:409.
15. Goc A, Liu J, Byzova TV, Somanath PR. 2012d. Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin beta(3) affinity modulation. Br J Cancer 107:713-723.
16. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. 2011. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071-1121.
17. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC, Jr., Amling CL, Freedland SJ. 2010. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116:3389-3398.
18. Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, Granfors T, Fowler CJ. 2012. Phospho-Akt immunoreactivity in prostate cancer: Relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS ONE 7:e47994.
19. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. 2006. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57:155-164.
20. Jakobisiak M, Golab J. 2010. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev 30:102-135.
21. Kochuparambil ST, AL-Husein B, Goc A, Soliman S, Somanath PR. 2011. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther 336:496-505.
22. Koutsilieris M, Mitsiades C, Sourla A. 2000. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: Development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol Med 6:251-267.
23. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. 2000. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010.
24. Kwak BR, Mulhaupt F, Mach F. 2003. Atherosclerosis: Anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2:332-338.
25. Li M, Losordo DW. 2007. Statins and the endothelium. Vascul Pharmacol 46:1-9.
26. Liao JK. 2005. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F-33F.
27. Liao JK, Laufs U. 2005. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89-118.
28. Mccabe NP, De S, Vasanji A, Brainard J, Byzova TV. 2007. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 26:6238-6243.
29. Nielsen SF, Nordestgaard BG, Bojesen SE. 2012. Statin use and reduced cancer-related mortality. N Engl J Med 367:1792-1802.
30. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. 2011. Statins and prostate cancer: Molecular and clinical aspects. Eur J Cancer 47:819-830.
31. Somanath PR, Chen J, Byzova TV. 2008. Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing. Angiogenesis 11:277-288.
32. Steffen BJ, Butcher EC, Engelhardt B. 1994. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am J Pathol 145:189-201.
33. Steiner O, Coisne C, Cecchelli R, Boscacci R, Deutsch U, Engelhardt B, Lyck R. 2010. Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium. J Immunol 185:4846-4855.
34. Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719.
35. Tantivejkul K, Kalikin LM, Pienta KJ. 2004. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91:706-717.
36. USPSTF. 2012. USPSTF Prostate Cancer Screening Recommendation: What are the benefits and harms of prostate cancer screening? [Online]. Available: http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm [Accessed 12/02/2012].
37. Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppanen-Laakso T, Virtanen J, Sankila A, Nordling S, Lundin J, Rannikko A, Oresic M, Kallioniemi O, Iljin K. 2011. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget 2:1176-1190.